Osborne N N
J Neurochem. 1981 Jan;36(1):17-27. doi: 10.1111/j.1471-4159.1981.tb02372.x.
The occurrence, metabolism, uptake, and release of noradrenaline were studied in the bovine retina with the following results. (1) Small amounts of noradrenaline occur in the retina and are restricted to the area corresponding to the inner nuclear and plexiform layers. (2) Retinal tissue can metabolise [14C]dopamine to form quantities of [14C]noradrenaline. (3) [14C]Noradrenaline can also be partly metabolised to form [14C]normetanephrine. (4) When bovine retinas were incubated with 5 x 10(-7) M-[3H]noradrenaline for 20 min and processes for autoradiography, most of the label was associated with apparent nerve processes in the inner plexiform layer. Biochemical analysis showed that more than 95% of the label was noradrenaline. (5) [14C]Noradrenaline uptake saturated with increasing noradrenaline concentrations and followed Michaelis-Menten kinetics. This uptake could be accounted for by two processes, a high-affinity system with a Km1 of 5 x 10(-8) M and a Vmax1 of 0.193 pmol/mg/10 min and a low-affinity system with a Km2 of 6.3 x 10(-5) M and a Vmax2 of 0.109 nmol/mg/10 min. (6) Noradrenaline uptake was strongly dependent on temperature and sodium, less dependent on potassium, and independent of calcium and magnesium ions. (7) Centrally acting drugs, such as desipramine, imipramine, desmethylimipramine, and amitriptyline, inhibited noradrenaline uptake by more than 55% at the concentration of 5 x 10(-5) M. These drugs at the same concentration diminished dopamine uptake by less than 30%. (8) Noradrenaline uptake is stereospecific, the (-) isomer having a greater affinity for the uptake sites than the (+) isomer. (9) [14C]Noradrenaline in the retina could be released by increasing the external potassium concentration. This release was calcium-dependent and was blocked by 20 mM-cobalt chloride. The present studies could be interpreted as supporting the idea that noradrenaline acts as a transmitter in the retina.
对牛视网膜中去甲肾上腺素的产生、代谢、摄取和释放进行了研究,结果如下:(1)视网膜中存在少量去甲肾上腺素,且局限于与内核层和神经丛层相对应的区域。(2)视网膜组织可将[14C]多巴胺代谢为一定量的[14C]去甲肾上腺素。(3)[14C]去甲肾上腺素也可部分代谢形成[14C]去甲变肾上腺素。(4)将牛视网膜与5×10(-7)M-[3H]去甲肾上腺素孵育20分钟并进行放射自显影处理时,大部分标记物与内神经丛层中明显的神经突起相关。生化分析表明,超过95%的标记物是去甲肾上腺素。(5)[14C]去甲肾上腺素摄取随着去甲肾上腺素浓度增加而饱和,并遵循米氏动力学。这种摄取可由两个过程解释,一个高亲和力系统,Km1为5×10(-8)M,Vmax1为0.193pmol/mg/10分钟;另一个低亲和力系统,Km2为6.3×10(-5)M,Vmax2为0.109nmol/mg/10分钟。(6)去甲肾上腺素摄取强烈依赖于温度和钠,对钾的依赖性较小,且与钙和镁离子无关。(7)中枢作用药物,如地昔帕明、丙咪嗪、去甲丙咪嗪和阿米替林,在5×10(-5)M浓度时抑制去甲肾上腺素摄取超过55%。这些药物在相同浓度时使多巴胺摄取减少不到30%。(8)去甲肾上腺素摄取具有立体特异性,(-)异构体对摄取位点的亲和力大于(+)异构体。(9)视网膜中的[14C]去甲肾上腺素可通过增加细胞外钾浓度而释放。这种释放依赖于钙,并被20mM氯化钴阻断。目前的研究可解释为支持去甲肾上腺素在视网膜中作为递质起作用这一观点。